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Peroxisome proliferator-activated receptor a (PPARa) is a ligand-
activated transcription factor belonging, together with PPARc and
PPARb/d, to the NR1C nuclear receptor subfamily. Many PPARa
target genes are involved in fatty acid metabolism in tissues with
high oxidative rates such as muscle, heart and liver. PPARa
activation, in combination with PPARb/d agonism, improves
steatosis, inﬂammation and ﬁbrosis in pre-clinical models of
non-alcoholic fatty liver disease, identifying a new potential ther-
apeutic area. In this review, we discuss the transcriptional activa-
tion and repression mechanisms by PPARa, the spectrum of
target genes and chromatin-binding maps from recent genome-
wide studies, paying particular attention to PPARa-regulation of
hepatic fatty acid and plasma lipoprotein metabolism during
nutritional transition, and of the inﬂammatory response. The roleJournal of Hepatology 20
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PPARa (NR1C1) is a ligand-activated nuclear receptor highly
expressed in the liver, initially identiﬁed as the molecular target
of xenobiotics inducing peroxisome proliferation in rodents [1].
Beside PPARa, the PPAR subfamily contains two other isotypes
encoded by the PPARb/d (NR1C2) and PPARc (NR1C3) genes, each
displaying isoform-speciﬁc tissue distribution patterns and func-
tions [2]. PPARa expression is enriched in tissues with high fatty15 vol. 62 j 720–733
; NAFLD; NASH; Fibrosis.
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r coactivator-1; ACOX1, acyl-CoA oxidase 1; LTB4, leukotriene B4; 8(S)-HETE, 8(S)-
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Table 1. Functional analysis of PPARa structural domains.
Domain PTM Function
N-term A/B AF-1 MAPK-dependent phosphorylation 
at Ser 6, 12 and 21
Ligand-dependent/independent activation function
Target gene specificity
C DBD Binding to PPRE
Interaction with cJun
D Hinge region PKC-dependent phosphorylation 
at Ser 179 and 230
SUMOylation at lysine 185
Providing NR structure flexibility
Potentiating NCoR recruitment
C-term E/F LBD/AF-2 SUMOylation at lysine 358 Ligand binding specificity
Interaction with RXR and p65
Interactions with multiple co-regulators e.g., CBP/p300 and SRC/p160
PPARa displays a classical NR canonical architecture. PPARa domains (from A to F) fulﬁl distinct functions by providing interaction surfaces with other TFs, co-regulators
and ligands, thus contributing to speciﬁc PPARa transcriptional regulation. PPARa undergoes several post-translational modiﬁcations (PTM) that markedly impact receptor
function (details in the text).
JOURNAL OF HEPATOLOGYacid oxidation (FAO) rates such as liver, heart, skeletal muscle,
brown adipose tissue, and kidney, although it is also expressed
in many tissues and cells including the intestine, vascular endo-
thelium, smooth muscle and immune cells such as monocytes,
macrophages and lymphocytes [3]. PPARa is a nutritional sensor,
which allows adaptation of the rates of fatty acid (FA) catabolism,
lipogenesis and ketone body synthesis, in response to feeding and
starvation [4]. PPARa is a transcriptional regulator of genes
involved in peroxisomal and mitochondrial b-oxidation, FA trans-
port and hepatic glucose production, the latter being rodent-
speciﬁc [5]. PPARa negatively regulates pro-inﬂammatory and
acute phase response (APR) signalling pathways, as seen in
rodent models of systemic inﬂammation, atherosclerosis and
non-alcoholic steatohepatitis (NASH) [6,7].
Dyslipidemia and chronic inﬂammation are frequent features
of non-alcoholic fatty liver disease (NAFLD), likely explaining the
association between cardiovascular disease (CVD) and NAFLD.
However, there is currently no approved NAFLD treatment. In
patients with atherogenic dyslipidemia, ﬁbrates acting as
synthetic PPARa agonists, lower plasma triglycerides and small
dense low density lipoprotein (LDL) particles, and raise high
density lipoprotein cholesterol (HDL-C) levels. Fibrates reduce
major cardiovascular events, especially in patients with high
triglyceride and low HDL-C [8]. Thus PPARa agonists may poten-
tially be useful in the management of NAFLD and co-morbidities
such as CVD. PPARa activation, in combination with PPARb/d
agonism, improves steatosis, inﬂammation and ﬁbrosis in rodent
models of NASH [9]. Thus, selective and potent PPARa modula-
tors (SPPARMs) and dual PPAR agonists constitute promising
strategies for the treatment of NAFLD. In this review, novel mech-
anistic insights into PPARa action, in hepatic lipid metabolism,
under different nutritional states, and its role in liver inﬂamma-
tion and ﬁbrosis are presented. We also summarize the (pre)
clinical ﬁndings on PPAR agonists under development for NAFLD
treatment.Functional analysis of PPARa structure
Canonical structure of PPARa
The human and mouse PPARa genes, respectively on chromo-
some 22 and chromosome 15, encode 468 amino acid polypep-
tides with 91% homology. In both species, the coding DNA
sequence spans the 30 region of exon 3, exons 4–7, and the 50Journal of Hepatology 201extremity of exon 8 [10]. PPARa has a canonical nuclear receptor
organization with six domains starting from the N-terminal A/B
to the C terminus F domain (Table 1). These domains integrate
intracellular signals to control the transcriptional activity of mul-
tiple target genes. The A/B domain contains the AF-1 region pro-
viding basal, ligand-binding-independent and -dependent
activity, which can be potentiated by MAPK phosphorylation of
serines 6, 12, and 21 [11]. Comparative studies of chimeric
PPARa/b/c proteins identiﬁed the AF-1 region as a determinant
of isotype-speciﬁc target gene activation [12]. The A/B domain
is connected to the DNA binding domain (DBD), harboring two
zinc-ﬁngers, which binds PPAR response elements (PPREs), local-
ized in gene regulatory regions and organized as direct repeats of
two hexamer core sequences AGG(A/T)CA, separated by one
nucleotide (DR-1). PPARa/b/c bind PPREs uniquely as heterodi-
mers with retinoid X receptor (RXR)a/b/c [13]. The A/T rich motif
upstream of the DR-1 provides a polarization signal of the
PPAR-RXR heterodimer, and may confer isotype-binding speciﬁc-
ity. Accordingly, PPARs interact with 50-extended hexamers,
whereas RXR binds to the downstream motif of the response ele-
ment [14]. The hinge region (domain D) is a highly ﬂexible
domain linking the DBD (domain C) and the ligand binding
domain (LBD). The structural integrity of the hinge region condi-
tions the interaction of PPARa with nuclear receptor corepres-
sors, such as NCoR, in the unliganded conformation [15]. The
hinge region is a target for post-translational modiﬁcations, such
as phosphorylation catalyzed by PKC on serines 179 and 230.
SUMOylation also targets the hinge domain of human PPARa at
lysine 185 and potentiates NCoR recruitment [16,17]. The
C-terminal LBD is the only domain of PPARa whose structure
has been solved by X-ray crystallography [18]. Similar to PPARc
and PPARb/d, the PPARa LBD is composed of a helical sandwich
ﬂanking a four-stranded b-sheet and contains the AF-2 helix.
The 1400 Å3 volume of the PPARa ligand binding pocket (LBP)
is only slightly different than the total volume of the 1600 PPARc
and 1300 Å3 PPARb/d LBPs [19,20]. Nevertheless, the PPARa LBP is
more lipophilic and less solvent-exposed than the LBPs of the
other PPARs, hence allowing the binding of more saturated FA.
In contrast to PPARc, the PPARa AF-2 helix is more tightly packed
against the LBD core when complexed with an agonist [21]. Crys-
tallography identiﬁed tyrosine 314 as the main determinant of
isotype ligand-speciﬁcity [18]. The AF-2 domain undergoes
ligand-dependent conformational changes, thereby directing var-
ious co-activators such as CBP/p300 and SRC-1, carrying LXXLL
motifs (L–leucine, X–any amino acid), to a hydrophobic cleft on5 vol. 62 j 720–733 721
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the PPARa LBD surface, thus promoting the formation of an active
transcriptional complex. The AF-2 domain may also play a role in
ligand-dependent gene repression. Agonist binding unmasks
lysine 358 in the LBD for SUMOylation, hence conferring repres-
sive activity to PPARa [22].
Endogenous and synthetic PPARa agonists
PPARa ligands are FA derivatives formed during lipolysis,
lipogenesis or FA catabolism. Substrates of the ﬁrst rate-limiting
peroxisomal b-oxidation enzyme, acyl-CoA oxidase 1 (ACOX1),
likely are PPARa agonists. Consistently, disruption of ACOX1 in
mice results in increased peroxisome proliferation, hepatocarci-
noma and elevated PPARa target gene expression [23,24].
Eicosanoid derivatives, including the chemoattractant LTB4 and
8(S)-HETE, the murine 8-LOX product from arachidonic acid,
are thought to be endogenous PPARa agonists [25]. The oxidized
phospholipid fraction of oxidized LDL enhances PPARa transcrip-
tional activity and induces its target gene, FATP-1, in human pri-
mary endothelial cells [26]. Liver-speciﬁc knockout of fatty acid
synthase (FAS), an enzyme catalysing the synthesis of FA,
resulted in hypoglycemia and liver steatosis when mice were
fed a fatdepleted diet, which was reversed by dietary fat or a
synthetic PPARa agonist, identifying products of FAS-dependent
de novo lipogenesis as PPARa activators [27]. Mass spectrometry
analysis on puriﬁed hepatic PPARa revealed the presence of 16:0/
18:1-GPC bound to its LBD in mice expressing hepatic FAS, but
not in liver-speciﬁc FAS knockout mice, identifying this phospho-
lipid as a FAS-dependent lipid intermediate and endogenous
PPARa ligand [28]. Adipose triglyceride lipase (ATGL)-dependent
hydrolysis of hepatic intracellular TG also yields lipid PPARa
ligands [29]. In line, overexpression of hepatic hormone-sensitive
lipase (HSL) and ATGL triggers PPARa-dependent FAO gene
expression and ameliorates hepatic steatosis [30].
A range of synthetic PPARa agonists, differing in species-
speciﬁc potencies and efﬁcacies, have been identiﬁed. Fibrates
such as gemﬁbrozil, fenoﬁbrate and ciproﬁbrate, are clinically used
in the treatment of primaryhypertriglyceridemia ormixeddyslipi-
demia [8]. However, ﬁbrates areweak PPARa agonistswith limited
clinical efﬁcacy [31]. Moreover, the potency of synthetic PPARa
agonists may differ between the human and mouse receptor, as
measured by using the PPARa-GAL4 transactivation system, i.e.,
fenoﬁbrate (mouse receptor, EC50 = 18,000 nM vs.human receptor,
EC50 = 30,000 nM), bezaﬁbrate (EC50 = 90,000 nM vs. 50,000 nM,
respectively) and Wy14,643 (EC50 = 630 nM vs. 5000 nM, respec-
tively) [32]. This may contribute to interspecies differences in
response to PPARa agonists that are detailed in the following
sections of this review. Potent and selective PPARa modulators
(SPPARMs), such as K-877 (EC50 = 1 nM) and GFT505 (EC50 = 6 nM
for PPARa), a dual PPARa/d agonist, are currently under develop-
ment for the treatment of atherogenic dyslipidemia and NAFLD,
respectively [31–33]. The therapeutic potential of novel PPAR
agonists on NAFLD is further discussed in this review.Mechanism of PPARa-dependent transactivation
Formation of transcriptionally active multiprotein PPARa complexes
Ligand-activated PPARa recruits numerous co-activator proteins,
including members of the CBP/p300 and SRC/p160 family, which722 Journal of Hepatology 201exhibitHATactivity, andother co-activators forming the transcrip-
tionally active PPARa-interacting cofactor complex [34]. Such
interactions are not seen with a PPARa AF-2 domain deleted
mutant [35]. Disruption of the Pbp/Med1 gene showed its essential
role in PPARa-dependent gene regulation. PBP/MED1 stabilizes
and directs a large transcription initiation complex containing
numerous co-activators and RNA polymerase II to the DNA-bound
PPAR-RXR heterodimer [36] (Fig. 1A). However, RXR homodimers
maybindDR-1PPREs independentof PPARaand inducePPARa tar-
get gene transcription through a co-activator-dependent mecha-
nism [37]. Recently, using a PPARa mutant (PPARaDISS), which
lacks PPRE-binding activity but maintains interactions with RXR
and transcriptional co-regulators, we showed that PPARa-driven
transactivation depends on PPRE binding in vitro, in human hepa-
toma HepG2 cells and in vivo in Ppara-deﬁcient mice with liver-
speciﬁc PPARaDISS expression [35].
Genome-wide transcriptomic and PPARa chromatin binding maps
Genome-wide localization and activity-occupancy studies
revealed that induction of PPARa target gene expression by PPARa
agonists is associated with increased binding of PPARa to chroma-
tin, rather by strengthening afﬁnity and stability of existing inter-
actions, than creating de novo ligand-inducible binding regions
[38]. Interestingly, almost half of the PPARa-binding regions in
human hepatoma cells are located within introns, whereas only
26%of themare localized in closevicinity (<2.5 kb)of the transcrip-
tion start site [39]. In addition, genome-wide proﬁling of liver X
receptor (LXR), RXR, andPPARa in themouse liver showedoverlap-
ping chromatin binding regions of LXR-RXR and PPARa-RXR het-
erodimers. Nevertheless, only a few percent of LXR and PPARa
binding sites contain consensus DR-4 and DR-1 elements, respec-
tively [38]. De novo motif analysis showed co-enrichment of
PPARa-binding regions in C/EBPa and TBP motifs, suggesting that
PPARa may inﬂuence gene expression through the formation of
complexes with other transcription factors [39]. Interestingly,
PPARa chromatin binding mapping, combined with transcripto-
mics in primary human hepatocytes treated with the synthetic
PPARa agonistWy14,643, showed that geneswhosepromoter reg-
ulatory regions are directly boundby PPARa via PPREs, are on aver-
agemore stronglyupregulated than genes inwhichPPARabinds to
theDNA indirectly [40]. Comparative transcriptomic studies in pri-
mary hepatocytes treated with Wy14,643 revealed only partial
overlapof up- (20%) or downregulated (12%) genesuponPPARa
activation, between humans and mice [41]. Nevertheless, search-
ing for enrichedbiological themes, inhumanandmouse sets of reg-
ulated genes by gene ontology (GO) classiﬁcation, showed a 50%
conservation in over-represented GO categories, mostly corre-
sponding to lipidmetabolic pathways [41]. Importantly, the glyco-
lytic and gluconeogenic pathwayswere speciﬁcally upregulated in
mice, whereas xenobiotic metabolism and apolipoprotein synthe-
sis pathways rather in human hepatocytes [41,42].Models of PPARa transcriptional repression
PPRE-independent transcriptional repression
PPARa negatively regulates pro-inﬂammatory signalling path-
ways via protein-protein interactions, a tethering mechanism
extensively studied in vitro and in mouse models of acute5 vol. 62 j 720–733
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Fig. 1. Models of PPARa transcriptional regulation. Several models of PPARa transcriptional regulation have been proposed, via which PPARamodulates expression of its
target genes as well as pro-inﬂammatory transcription factors and acute phase response genes. (A) Formation of the PPRE-dependent ligand-activated transcriptional
complex containing PPARa-RXR heterodimer, co-activators, HAT, PBP/MED1 and the transcriptional preinitiation complex (PIC). (B) PPRE-dependent inhibition of NFjB
transcriptional activity. Upon ligand activation, DNA-bound PPARa directly interacts with p65 to abolish its binding to an NFjB response element (NRE) in the complement
C3 promoter. (C) PPARa directly interacts with pro-inﬂammatory transcription factors cJun and p65 to negatively regulate their target genes by a mechanism that is
thought to be PPRE-independent. (D) Simultaneous ligand-activation of GR and PPARa leads to the enhanced repression of TNF-induced IL-6 transcriptional activity, by the
mechanism that stems from a direct GR-PPARa physical interaction. (E) PPARa downregulates ﬁbrinogen b transcriptional activity via ligand-dependent mechanisms,
engaging physical interaction between PPARa and GRIP-1/TIF-2.
JOURNAL OF HEPATOLOGYinﬂammation. Ligand-activated PPARa represses cytokine-
induced IL-6 gene expression via interference with AP-1 and
NFjB signalling pathways. PPARa-driven transrepression
involves direct physical interactions between PPARa, the p65
Rel homology domain, and the N-terminus JNK-responsive part
of cJun (Fig. 1C) [43]. Moreover, synergistic transrepression of
NFjB-driven gene expression occurs upon simultaneous activa-
tion of PPARa and glucocorticoid receptor (GR), a well-character-
ized NFjB repressor (Fig. 1D) [44]. However, PPARa and GR
transrepress distinct but overlapping sets of genes in vascular
endothelial cells [45]. PPARa activation downregulates hepatic
APR genes, such as Fib, Saa, and Hg in rodents, and CRP in human
hepatocytes. Mechanistically, PPARa downregulates mRNA and
protein levels of GP80 and GP130, components of the IL6-recep-
tor, thus disrupting the STAT3 and cJun signalling pathways
involved in the APR [6]. Similarly, in the liver, ﬁbrates downregu-
late IL-6-stimulated Fib-b expression via PPARa-dependent titra-
tion of GRIP-1/TIF-2, thus interfering with C/EBPb activityJournal of Hepatology 201(Fig. 1E) [46]. Another mechanism of PPARa-dependent tran-
scriptional repression occurs in the control of ERR-driven
mitochondrial respiration and cardiac contraction, where a
PPARa-SIRT1 complex binds directly to a single hexameric ERRE
motif, thus competitively downregulating ERR target genes
[47,48]. Recently, we showed that hepatic PPARa represses
cytokine- and LPS-induced inﬂammatory responses in vitro and
in vivo, independently of direct DNA binding [35].
PPRE-dependent transcriptional repression
Recently, a novel PPRE-dependent model of transcriptional regu-
lation has been proposed, through a negative crosstalk between
PPARa and p65, diminishing complement C3 promoter transcrip-
tional activity in a human hepatoma cell line. Ligand-dependent
activation of PPARa inhibits TNF-mediated upregulation of com-
plement C3 through the physical interaction between PPRE-
bound PPARa and p65, to abolish p65 binding to the upstream5 vol. 62 j 720–733 723
Review
NFjB response element on the complement C3 promoter (Fig. 1B)
[49]. In line with these observations, genome-wide studies
revealed the presence of STAT-PPAR binding motifs within
ligand-inducible PPARa binding regions of downregulated genes.
This suggests a direct negative crosstalk between PPRE-bound
PPARa and pro-inﬂammatory transcription factors [39].
Key Points 1
Transcriptional regulation by PPARα 
• Transactivation: PPARα recognizes and binds to PPREs 
located in the regulatory regions of its target genes
• Transrepression: PPARα directly or indirectly interacts 
with transcription factors to block their transcriptional 
activity
• PPARα target genes related to fatty acid oxidation are 
regulated mainly in a PPRE-binding dependent manner
• Expression of pro-inflammatory genes can be repressed 
by PPARα either via PPRE-binding dependent or 
PPRE-binding independent mechanisms. Further 
studies are needed to understand the mechanisms of 
PPRE-independent PPARα activitiesRegulation of fatty acid metabolism by PPARa
PPARa-regulated FA transport and oxidation
FA are transported in cells by membrane-associated FATPs [50].
FATP1, which catalyses ATP-dependent esteriﬁcation of LCFA
and VCFA into acyl-CoA derivatives, is a direct PPARa target gene
[51,52]. Another plasma membrane FA transporter, FAT/CD36, is
positively regulated by PPARa ligands [53]. Functional PPREs
were identiﬁed within the promoter of the intracellular lipid traf-
ﬁcking L-Fabp [54]. Direct protein-protein interaction were
reported between PPARa and L-FABP, suggesting that L-FABP
may channel PPARa ligands to the receptor [55,56]. Consistently,
a positive correlation between L-FABP protein and PPRE-driven
gene transcription was observed in human hepatoma HepG2
cells, treated with PPARa agonists [57].
PPARa controls gene expression levels of the rate-limiting
enzymes of peroxisomal b-oxidation, including ACOX1 and
EHHADH, most pronouncedly in rodents [41]. In rodents and pri-
mates, FA transport across the mitochondrial membrane is trig-
gered by PPRE-dependent regulation of CPT-I and CPT-II, which
proteins are localized in the outer and inner mitochondrial mem-
brane respectively [58–60]. Moreover, PPARa regulates the criti-
cal reaction of mitochondrial b-oxidation by directly controlling
MCAD, LCAD, and VLCAD expression levels [61,62].
Enhanced expression of peroxisomal genes involved in lipid
metabolism is related to the induction of peroxisome proliferation
by PPARa agonists, which may contribute to tumorigenesis in
rodents [63]. A comparative study between mouse and human
PPARa expressed in Ppara-deﬁcient mice revealed that
Wy14,643 induces mouse liver peroxisomal proliferation in a
receptor species-independent manner [64]. However, long-term
Wy14,643 treatment induced liver tumors only in 5% of PPARa724 Journal of Hepatology 201humanized mice, whereas the incidence of hepatocellular carci-
noma was 71% in wild-type mice [65]. Mechanistically, murine
but not human PPARa downregulated the expression of let-7C,
an miRNA targeting the c-myc oncogen [66]. Moreover, long-term
treatment of hyperlipidemic patients with either gemﬁbrozil or
fenoﬁbrate showed no effect on peroxisomal proliferation and
hepatocyte hyperplasia, as assessed by light and electron micros-
copy of liver biopsies [67,68]. Importantly, a meta-analysis of
long-term randomized controlled trials demonstrated neutral
effects of ﬁbrate treatment on cancer [69].
PPARa and ketogenesis
During fasting, hepatic FAO increases, yielding acetyl-CoA which
is further converted into ketone bodies. Ligand-activated PPARa
upregulates mitochondrial HMGCS, a rate-limiting enzyme of
ketogenesis, which catalyses condensation of acetyl-CoA and ace-
toacetyl-CoA to generate HMG-CoA and CoA [70]. Themild pheno-
type of Ppara-deﬁcient mice fed ad libitum became more
pronounced during fasting, being characterized by impaired
FAO, lipid accumulation in liver and heart as well as hypoglycemia
and an inability to augment ketone body synthesis [71,72]. More-
over, high-fat, low-carbohydrate ketogenic diet (KD)-feeding
increased hepatic mRNA expression and plasma levels of FGF21,
in parallel with PPARa induction [73]. Fgf21 knock-down in KD-
fed mice impaired hepatic expression of FAO genes (Acox1, Cpt-
I) and ketogenesis (Hmgcs, Bdh), indicating that FGF21 is required
for the activation of these metabolic pathways [73]. Further stud-
ies identiﬁed FGF21 as a direct PPARa target gene, induced, in
mice and humans, in response to fasting and upon PPARa ligand
administration [73,74].PPARa in the regulation of hepatic lipid and plasma
lipoprotein metabolism
Molecular insights into the lipid normalizing effects of PPARa
In rodent models, the reduction of plasma TG-rich lipoprotein
upon PPARa activation is related to enhanced FA uptake, conver-
sion into acyl-CoA derivatives, and further catabolism via the
b-oxidation pathways.Moreover, the TG-lowering action of PPARa
is also due to increased lipolysis via induction of lipoprotein lipase
(LPL), which catalyses the hydrolysis of lipoprotein TG into free FA
andmonoacylglycerol. PPARa controlled LPLmRNA through bind-
ing to a PPRE in the human and mouse LPL gene promoters [75].
Furthermore, PPARa enhanced LPL activity indirectly by decreas-
ingmRNA levels and secretion of hepatic APO-CIII, an LPL inhibitor
[76]. Interestingly, glucose induced APO-CIII transcription in
hepatocytes through a mechanism involving the transcription
factors ChREBP and HNF-4 [77]. Conversely, hepatic expression
of APO-CIII was inhibited by insulin through insulin-dependent
phosphorylation of FOXO1, resulting in its displacement from the
nucleus and inability to drive APO-CIII transcriptional activity
[78]. In hepatocytes, inhibition of APO-CIII transcription by ﬁbrates
was the consequence of multiple cooperative mechanisms
including PPARa-driven displacement of HNF-4 from the APO-CIII
promoter, inhibition of FOXO1 activation of APO-CIII transcription
via the insulin-responsive element, and inhibition of glucose-
stimulated APO-CIII expression [76,79].
In humans, ﬁbrates increase plasma HDL-C by stimulating the
synthesis of its major apolipoproteins, APO-AI and APO-AII.5 vol. 62 j 720–733
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However, species-differences exist between humans and rodents
with respect to apolipoprotein regulation by PPARa. A functional
PPRE is present in the human, but not rodent APO-AI promoter, as
illustrated by increased human APO-AI production in humanized
Apo-AI transgenic mice upon treatment with ﬁbrates [80]. In con-
trast, APO-AI and HDL-C levels are elevated in Ppara-deﬁcient
mice and ﬁbrate treatment decreases Apo-AI mRNA in wild-type
animals [81,82]. In the human and mouse liver, APO-AII expres-
sion is induced by PPARa. Hepatic human APO-AII gene transcrip-
tion is induced by PPARa through interaction with a PPRE
localized within the APO-AII promoter region. A functional PPRE
could not be identiﬁed within the mouse Apo-AII promoter [83].
However, based on available data from genome-wide PPARa
binding map, we inspected through promoter regions of hepatic
mouse Apo-AII for the presence of PPARa ChIP-seq peaks [38]
and identiﬁed a PPARa binding also in the mouse Apo-AII proxi-
mal promoter, 100 bp downstream of the transcription start site
(our unpublished data). Similar species-speciﬁc transcriptional
regulation modes are observed for APO-AV, which enhances LPL
activity, by PPARa [84,85]. Studies using human LPL transgenic/
Apo-AV-deﬁcient mice and human APO-AV transgenic/Lpl-
deﬁcient mice support the hypothesis that APO-AV reduces TG
levels by trafﬁcking VLDL and chylomicrons to proteoglycan-
bound LPL for lipolysis [86,87]. In vitro and in vivo studies com-
paring wild-type versus transgenic humanized APO-AV mice
revealed that human, but not mouse APO-AV expression is
induced in the liver by PPARa agonists [88,89]. These ﬁndings
are consistent with the identiﬁcation of a functional PPRE in
the human, but not mouse Apo-AV promoter [88,89]. In humans,
rare SNPs in the APO-AV promoter region are associated with par-
adoxical decreases in plasma HDL-C and APO-AI in response to
ﬁbrates, whereas SNPs within the APO-AV gene are associated
with enhanced lipid response to ﬁbrate and statin therapy
[90–93]. Thus, unexpected responses to ﬁbrate treatment in some
individuals may be due to genetic variations in PPARa target
genes, such as APO-AV.
PPARa and hepatic lipogenesis
Besides its ability to orchestrate lipoprotein metabolism, PPARa
also controls, directly or indirectly, lipogenic pathways in the
liver. Lipogenesis is the metabolic pathway allowing FA synthesis
when dietary carbohydrates are abundant. Dietary regulation of
hepatic lipogenic genes is under control of the insulin-dependent
transcription factors SREBP-1c and ChREBP [94]. PPARa agonists
enhance human SREBP-1c transcriptional activity through PPARa
interacting with a DR-1 element in the human SREBP-1c promoter.
Consistently, PPARa binding to the human SREBP-1c promoter is
demonstrated in vitro and in vivo, in human primary hepatocytes
[95]. In mouse livers, the SREBP-1c target genes Fas, Acc1, and
Scd-1 are positively regulated by PPARa agonists [96,97]. Never-
theless, neither Srebp-1c nor its downstream targets have been
identiﬁed as direct PPARa target genes inmice, with the exception
of Scd-1, which contains a PPRE in its promoter [97]. In mice,
ﬁbrates increase the protein levels of the mature hepatic form of
SREBP-1c, by increasing the rate of proteolytic cleavage of its
membrane-bound precursor form, without changing Srebp-1c
mRNA levels [98]. The insulin-dependent enhancement of
SREBP-1c transcription requires the participation of LXR and
SREBP-1c itself [99]. Moreover, via LXR-binding sites in the
human and mouse Srebp-1c promoter, LXR agonists induce itsJournal of Hepatology 201transcriptional activity [95,100]. PPARa can also indirectly modu-
late SREBP-1c transcription via cross-regulation with the LXR
signaling pathway. In mice, PPARa is required for the LXRa-
dependent response of SCD-1 and FAS to insulin in re-fed condi-
tions, suggesting a potential role for PPARa in the synthesis of
endogenous LXRa ligands [101]. In human primary hepatocytes,
PPARa agonists, cooperatively with insulin and LXR agonists,
induce lipogenic gene expression, such as FAS and ACC1 [95].
Key Points 2
PPARα-dependent activities in mice and humans
• Fatty acid metabolism and ketogenesis are the most 
conserved PPARα-regulated biological processes 
between mice and humans
• Regulation of the glycolysis-gluconeogenesis pathway 
by PPARα agonists occurs in mice, but not in men
• Xenobiotic metabolism and apolipoprotein synthesis 
pathways are specifically controlled by PPARα agonism 
in human hepatocytes
• Peroxisomal proliferation genes are induced upon 
activation of both human and mouse PPARα, 
however, humans are protected from fibrate-induced 
tumorigenesisHepatic PPARa activity switches in the fed-to-fasted transition states
PPARa coordinates different pathways of de novo lipid synthesis
in the fed state, to supply FA for storage as hepatic TG, for periods
of starvation. During fasting, when the organism switches to the
utilization of FA, deriving either from the liver or from peripheral
tissues, PPARa also shifts its activity to promote FA uptake and b-
oxidation, thus yielding substrates for ketone body synthesis to
provide energy for peripheral tissues (Fig. 2). The adjustment of
PPARa transcriptional activity in the adaptation to fasting/feed-
ing transition can be potentially brought about by kinases con-
trolled by different nutritional states and phosphorylating
PPARa or its regulatory proteins.
Several kinases, including PKA, PKC, and MAPK, have been
shown to modify PPARa transcriptional activity (see also Table 1),
although many studies were performed in vitro, and thus lack
physiological translation to the coordinated responses to differ-
ent nutritional signals in the living organism. However, insulin-
activated MAPK and glucose-activated PKC stimulate PPARa
transactivation in HepG2 cells [16,102], suggesting that MAPK-
and PKC-dependent phosphorylations may promote PPARa activ-
ity in the post-prandial state. Conversely, in fasting, glucagon
induces cAMP and cAMP-dependent kinase PKA activity [103].
PKA-mediated phosphorylation potentiates ligand-dependent
PPARa activation and increases expression of FAO genes in mouse
primary hepatocytes [104].
Studies performed in mice hint that mTORC1 also plays a role
in switching PPARa activities during the feeding/fasting transi-
tion as well as in pathophysiological conditions. In the fed state,
when mTORC1 is activated by the insulin-dependent PI3K path-
way, NCoR1 is partitionned in the cytoplasm and the nucleus of
hepatocytes, thus repressing PPARa target gene expression5 vol. 62 j 720–733 725
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Fig. 2. Molecular switch of PPARa activity in the fed-to-fasted state. Augmented postprandial glucose levels lead to increased production and secretion of insulin by
b-cells, which acts on the liver to induce glucose uptake and glycolysis, yielding acetyl-CoA (AcCoA), and enhances FA synthesis. Insulin stimulates PPARa phosphorylation
via PKC and enhances its transcriptional activity, whereas insulin-activated mTORC1 blocks PPARa activity by promoting nuclear localization of NCoR. Lipogenesis yields
fatty acid-derivatives operating as PPARa ligands. During fasting, stress hormones such as adrenaline and glucocorticoids are synthesized together with glucagon. Glucagon
sustains gluconeogenesis through a stimulatory effect on hepatic gluconeogenic precursor uptake as well as on the efﬁciency of gluconeogenesis within the liver. Moreover,
glucagon increases cAMP levels triggering PKA-dependent PPARa phosphorylation and activity. Fasting leads to decreased mTOR1C activation and stimulation of PPARa-
dependent FAO and ketogenesis. The lipolytic release of adipose tissue fatty acids raises plasma levels of free fatty acids (FFA) that are subsequently stored in the liver as TG.
ATGL-dependent hydrolysis of hepatic intracellular TG provides lipid ligands for PPARa activation. PPARa activation leads to increased b-oxidation rates directly and via
FGF21 activation to provide substrates for ketone body synthesis and gluconeogenesis, thus maintaining energy sources for peripheral tissues. During prolonged fasting,
high intracellular AMP levels induce AMPK to stimulate energy production by PPARa-driven FAO.
Review[105]. Inhibition of mTORC1 and its downstream effector S6K2
during fasting promotes a cytoplasmic relocalization of NCoR1,
hence increasing ketogenesis via PPARa derepression [105,106].726 Journal of Hepatology 201Interestingly, S6K2 phosphorylation is elevated in ob/ob mice, a
model of obesity and insulin resistance (IR) [106]. The ability of
FAS to synthesize phospholipids, acting as endogenous PPARa5 vol. 62 j 720–733
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ligands, depends on its subcellular localization and post-transla-
tional modiﬁcations [107]. Insulin-dependent phosphorylation of
cytoplasmic FAS by mTORC1 limits PPARa ligand generation,
whereas membrane-associated FAS, producing lipids for energy
storage and export, is less susceptible to phosphorylation. Con-
versely, in the fasting state, de-phosphorylated cytoplasmic FAS
is in a permissive state, allowing the generation of endogenous
PPARa ligands, thus activating PPARa-target genes [107].
Hepatic PPARa activity can also be stimulated by AMPK, a sen-
sor of the intracellular energy state activated by high AMP-to-ATP
ratios, i.e., during fasting [108]. In contrast, glucose represses
PPARa gene expression via AMPK inactivation in pancreatic
b-cells [109,110], although it is unknownwhether a similar mech-
anism occurs in the liver. Adiponectin, an insulin-sensitizing
adipokine, increases FAO gene expression via AMPK-dependent
PPARa activation [111]. Serum adiponectin is decreased in obesity
and T2DM [112], which may contribute to an impaired PPARa
activity in these pathologies.PPARa in acute and chronic liver inﬂammation
PPARa and acute hepatic inﬂammation
PPARa exerts anti-inﬂammatory activities in murine models of
systemic inﬂammation. PPARa agonism speciﬁcally attenuates
the IL-6-induced APR in vitro and in vivo, by downregulating
hepatic expression levels of Saa, Hg, and Fib-a, -b and -c [6]. Sim-
ilar inhibitory effects of PPARa agonists on IL-1b- and IL-6-
induced APR were observed in mice with liver-restricted Ppara
expression [113]. By contrast, treatment with IL-1b decreases
expression of liver PPARa and its target genes, suggesting a neg-
ative crosstalk between IL-1b-induced inﬂammation and hepatic
FAO regulation [114]. In line with these observations, LPS-
induced APR is counteracted by ﬁbrates in Ppara-deﬁcient mice
with liver-speciﬁc reconstituted Ppara [113]. Interestingly, pre-
treatment with a PPARa agonist markedly prevents the LPS-
induced increase of plasma IL-1, IL-6, and TNF, and the expression
of adhesion molecules, such as ICAM-1 and VCAM-1 in the aorta,
suggesting that liver PPARa controls, in a yet undeﬁned manner,
the systemic inﬂammatory response [113]. The anti-inﬂamma-
tory effects of hepatic PPARa may also derive from its ability to
upregulate anti-inﬂammatory genes, such as Il-1ra and IjBa, a
cytoplasmic inhibitor of NFjB, suggesting a possible cooperation
between PPARa-dependent transactivation and transrepression
to turn on anti-inﬂammatory pathways [115,116].
PPARa action in pre-clinical models of NAFLD
NAFLD is a chronic liver disease, which affects 10–24% of the pop-
ulation and is associated with IR and the MetS [117]. The pathol-
ogy initiates with hepatic steatosis, which in some individuals
progresses toward NASH, ﬁbrosis, cirrhosis and ﬁnally liver fail-
ure. The ability of PPARa to counteract different stages of NAFLD
has been studied in animal models, which partially replicate the
human pathology [118].
Administration of an methionine choline-deﬁcient diet
(MCDD) to rodents leads to the development of steatohepatitis,
histologically similar to human NASH. However, MCDD does
not induce peripheral IR, normally observed in human
NASH. Ppara-deﬁciency in MCDD-fed mice provokes more severeJournal of Hepatology 201steatosis and hepatitis [7]. In wild-type mice, PPARa agonism
normalizes histological changes by preventing intrahepatic lipid
accumulation, liver inﬂammation, and ﬁbrosis [119]. Pharmaco-
logical activation of PPARa increases CYP4A-driven x-oxidation
as well as peroxisomal and mitochondrial b-oxidation, leading
to enhanced hepatic lipid turnover. Moreover, synthetic PPARa
agonists decrease the number of activated macrophages and stel-
late cells in the liver, and lower the expression of ﬁbrotic markers
[7]. In rodents, PPARa appears to be expressed mainly in hepato-
cytes [120], suggesting that the hepatoprotective effects of
ﬁbrates in rodents likely occur via PPARa within liver parenchy-
mal cells (Fig. 3). We showed that the hepato-speciﬁc expression
of the DNA-binding disabled PPARaDISS protects from MCDD-
induced inﬂammation and liver ﬁbrosis, without affecting FAO
genes and lipid accumulation in the liver [35]. Hepatoprotective
effects of PPARa agonism can also occur via the regulation of
hepatic Vnn1 expression [121], since Vnn1-deﬁciency links hepa-
tic steatosis in response to fasting and changes the expression of
inﬂammation and oxidative stress genes [122]. The role of ATGL-
dependent intracellular TG hydrolysis, to generate endogenous
PPARa agonists with anti-inﬂammatory potential, was recently
demonstrated in Atgl-deﬁcient mice [123], which display
increased susceptibility to LPS- and MCDD-induced hepatic
inﬂammation due to impaired PPARa signaling. The hepatic phe-
notype of Atlg-deﬁcient mice is partially improved upon treat-
ment with a synthetic PPARa agonist. The foz/foz (ALMS1
mutant) mouse model of Alström syndrome spontaneously
exhibits a strong metabolic phenotype hallmarked by severe
obesity, hyperinsulinemia and T2DM [124–126]. In this genetic
background, PPARa activation reverses HFD-induced hepatocel-
lular injury, liver inﬂammation and improves insulin sensitivity
[127]. Similarly, Ppara-deﬁciency promotes HFD-induced hepatic
TG, macrophage inﬁltration and elevates plasma levels of ALT and
SAA [128]. In contrast to the observation that PPARa activation
improves insulin sensitivity [129], Ppara-deﬁcient mice are pro-
tected from HFD-induced IR, as assessed by glucose tolerance test
and euglycemic-hyperinsulinemic clamps in fasted mice
[129,130]. Similar tests performed in non-fasted Ppara-deﬁcient
mice, however, show no protection from IR compared to wild-
type mice [131]. These contradictions can result from the
impaired response to fasting in Ppara-deﬁcient mice, in which
the inability to oxidize FA leads to a preferential glucose use
and depletion of glycogen stores [132].
The development of early stages of NASH was studied in the
humanized APO-E2 knock-in (APO-E2KI) mouse. In this model,
the Apo-E gene has been substituted for the human APOE2 allele
under the control of the endogenous mouse promoter, faithfully
mimicking mouse endogenous APO-E tissue distribution and
expression levels. The reduced afﬁnity of hAPO-E2 for the LDL-
receptor leads to a plasma lipoprotein proﬁle similar to that
occurring in human type III hyperlipoproteinemia [118]. APO-
E2-KI mice fed a western diet rapidly develop a phenotype char-
acterized by steatosis and inﬂammation. Interestingly, macro-
phage inﬁltration in the liver precedes lipid accumulation. This
is in contradiction with the concept that NASH pathogenesis
always stems from initial liver steatosis, which leads to inﬂam-
mation [133]. In accordance, clodronate liposome-induced deple-
tion of residual liver macrophages (Kupffer cells) reduces hepatic
TG content in HFD-fed wild-type mice [114]. Western diet-fed
Ppara-deﬁcient/APO-E2-KI mice manifest exacerbated liver stea-
tosis and inﬂammation compared to wild-type APO-E2-KI mice,5 vol. 62 j 720–733 727
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Fig. 3. Hepatoprotective effects of ﬁbrates: examples from rodent models of NAFLD. Development of NASH is provoked by different risk factors, such as Western-type
diet, physical inactivity and genetic predispositions that often lead to insulin resistance and T2DM. Exaggerated food intake leads to FA synthesis via hepatic lipogenesis
pathways. Enhanced TG storage in the liver (steatosis) provokes uncontrolled lipid peroxidation that generates reactive oxygen species (ROS) and cytotoxic aldehydes.
Hepatocyte damage leads to increased inﬂammatory signaling (IL-1, TNF), acute phase response (APR) and recruitment of circulating (Mu) and residual macrophages (KC).
All of these mechanisms can directly induce apoptosis, necrosis and TGFb-dependent activation of hepatic stellate cells (HSC) that are the main source of extracellular
matrix protein in liver, thus contributing in ﬁbrosis progression. In several mouse models of NAFLD, ﬁbrate-activated PPARa counteracts different stages of NAFLD by
promoting FAO and hampering pro-inﬂammatory response. Moreover, ﬁbrate treatment induces catalase (CAT) expression thus diminishing H2O2 levels in the liver.
Hepatic cirrhosis is associated with endothelial dysfunction and impaired intrahepatic hemodynamics that may lead to liver failure. Fibrates improve and ameliorate
hepatic vascular resistance by reducing cyclo-oxygenase-1 (COX-1) protein expression.
Reviewindicative of a protective role of PPARa against NASH [134]. Con-
sistently, in primary hepatocytes isolated from APO-E2-KI mice,
HFD induces an aberrant histone H3K9me3 and H3K4me3 meth-
ylation proﬁle of the promoter of Ppara, which correlates with
decreased Ppara mRNA expression [135]. In APO-E2-KI mice
expressing PPARa, ﬁbrates inhibit NASH due to their inhibitory
effects on pro-inﬂammatory genes and the increase in lipid
catabolism in the liver [133,134]. Among the ROS, hydrogen per-
oxide is a major agent activating TGFb and collagen production
by hepatic stellate cells [136,137]. The anti-ﬁbrotic action of syn-
thetic PPARa agonists was demonstrated in a rat model of thioac-
etamide-induced liver cirrhosis. PPARa directly upregulates
catalase expression, thus ameliorating hydrogen peroxide detox-
iﬁcation and protecting hepatocytes from oxidative stress [138].
Moreover, ﬁbrates improve endothelial dysfunction and amelio-
rate intrahepatic hemodynamics in CCl4 cirrhotic rats, at least
in part, by reducing COX-1 protein expression [139].
PPARa agonism in NAFLD therapy
Few clinical pilot studies were performed to assess the impact of
ﬁbrates, which improve atherogenic dyslipidemia, on the evolu-
tion of NASH. Fenoﬁbrate treatment (48 weeks) of 16 patients728 Journal of Hepatology 201with biopsy-conﬁrmed NAFLD reduces the proportion of patients
with elevated ALT, AST and cGT plasma levels and histologically-
assessed hepatocellular ballooning [140]. However, the grade of
steatosis, inﬂammation and ﬁbrosis is not signiﬁcantly changed
upon fenoﬁbrate treatment, in this relatively small, phenotypi-
cally heterogeneous cohort [140]. Short-term bezaﬁbrate treat-
ment (2–8 weeks), combined with diet and exercise, of donors
for liver transplantation with steatosis decreases macrovesicular
steatosis [141]. Treatment of NASH patients (4 weeks) with gem-
ﬁbrozil lowers ALT, AST, and cGT plasma levels [142]. Treatment
with cloﬁbrate (12 months) of 16 patients with NASH does not
improve either ALT, AST and cGT or histologically assessed stea-
tosis, inﬂammation and ﬁbrosis [143]. However, serum TG does
not decrease in these hypertriglyceridemic patients, casting
doubts on the treatment efﬁcacy. Larger randomized studies
evaluating the action of novel PPARa agonists with SPPARM
activity, on a broad spectrum of liver pathologies and combining
several methods of NAFLD assessment, are still to be performed
to unequivocally assess their efﬁcacy. Moreover, despite numer-
ous reports of beneﬁcial effects of ﬁbrates in mice, species-spe-
ciﬁc differences may exist in the response to PPARa agonism
[32]. The relatively weak potency of the currently used PPARa
agonists in humans can be additionally affected by the lower5 vol. 62 j 720–733
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expression level of PPARa in the human compared to mouse liver
[144,145]. Importantly, we found that hepatic Ppara expression
decreases with progressive stages of liver ﬁbrosis in patients with
NASH (our unpublished data). Thus, novel PPARa agonists with
greater potency and efﬁcacy may prove to be more useful in
the treatment of NAFLD. Amongst these, K-877 manifests greater
efﬁcacy than ﬁbrates in terms of TG-lowering activity. Moreover,
K-877 raises plasma FGF21 levels in Ldlr-deﬁcient mice fed a
Western diet [31]. Consistently, Phase II clinical trials showed
better efﬁcacy of K-877 treatment on fasting plasma TG and
HDL-C, in individuals with atherogenic dyslipidemia, in compar-
ison to fenoﬁbrate [31]. These data suggest that K-877 could be a
novel treatment option to tackle the residual cardiovascular risk.
So far no data are available on the effects of K-887 on NAFLD.
Recently, GFT505 was shown to counteract multiple stages of
NAFLD, as assessed in several animal models of NASH and ﬁbrosis
[9,146], effects likely due to the combined activation of the
PPARa and d receptors. GFT505 exerts preventive effects on liver
steatosis and inﬂammation, induced in APO-E2-KI mice by a
Western-diet and in db/db mice by an MCDD. Furthermore,
GFT505 exerts anti-ﬁbrotic activities on CCl4-induced ﬁbrosis in
rats [9]. In phase II clinical trials, GFT505 treatment decreases
plasma concentrations of ALT, cGT, and ALP, in MetS patients
[9]. Considering its ability to improve peripheral insulin sensitiv-
ity and lower plasma FFA levels, likely via PPARd activation, in
abdominally obese patients, as well as its TG lowering/HDL
increasing activity in subjects with combined dyslipidemia,
GFT505 is a promising drug candidate for the treatment of
diseases linked to IR, such as T2DM and NASH [146,147].
Key Points 3
PPARα activities in NASH and in liver fibrosis
• PPARα deficiency leads to exaggerated lipid 
accumulation in the liver
• Pharmacological PPARα activation decreases liver 
steatosis by increasing FAO gene expression
• PPARα agonism diminishes chronic liver inflammation 
and fibrosis independent of its effect on liver steatosis
• The dual PPARα/δ agonist GFT505 is currently tested 
in a phase IIb trial for the therapy of NASH in metabolic 
syndrome and type 2 diabetes
PerspectivesGenome-wide approaches have shown that PPARa is a master
regulator of FA metabolism and ketogenesis in the liver [41].
The ability of PPARa agonists to counteract steatohepatitis and
ﬁbrosis appears prominent in murine models of NAFLD, which
can be explained by the fact that PPARa expression is more abun-
dant in the mouse compared to human liver and may further
decrease with NASH progression (our unpublished data). More-
over, commonly used ﬁbrates are relatively low activators of
human PPARa. Thus potent and highly speciﬁc PPARa agonists,
such as K-877 and the dual PPARa/d agonist GFT505, have
appeared as promising therapies for CVD or NAFLD, respectively.
Nevertheless, further clinical studies are required to determine
the effectiveness and safety of such SPPARMs in humans. SinceJournal of Hepatology 201the anti-inﬂammatory and anti-ﬁbrotic activities of PPARa seem
to be dissociable from its effect on liver steatosis in mice [35],
more potent, possibly selective transrepression-triggering PPARa
agonists could be designed in the future, based on virtual drug
screening and transcriptomics. A better understanding of PPARa
regulation by different nutritional signals in healthy individuals
and in MetS patients will allow the design of speciﬁc pharmaco-
logical therapies, simultaneously targeting different NASH-
triggering factors. Moreover, to improve NASH, dietary strategies,
such as n-3 PUFA supplementation may be considered to amelio-
rate steatosis and inﬂammation, by a mechanism that may par-
tially rely on PPARa activation [148,149]. However, the efﬁcacy
of n-3 PUFA in the treatment of NASH in human subjects remains
to be demonstrated.Conﬂict of interest
BS is an advisor of Genﬁt SA.
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